Open access
Aug 2026
Elevated DYRK1A in Primary Tauopathies and Therapeutic Targeting with the Brain-Penetrant Inhibitor DYR533
An association between elevated DYRK1A and disease severity in human primary tauopathies is established and pharmacological inhibition of DYRK1A with DYR533 reduces pathological tau phosphorylation and neuroinflammatory signaling in vivo.
R. Velazquez, Samantha K. Bartholomew, W. Winslow et al.
· Research Square · 0 citations